Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 2/20 | 0.45 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989296 | 0.93 | SPPL2A (0.53) | SPPL2APSMB1ADORA3ADORA2AADORA2B | |
| SCHEMBL2576523 | 0.92 | PSMB1 (0.52) | SPPL2APSMB1ADORA3ADORA2AADORA2B | |
| SCHEMBL11988786 | 0.89 | SPPL2A (0.69) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL11989380 | 0.86 | SPPL2A (0.54) | SPPL2ABACE1RENCTSDMLNR | |
| SCHEMBL9119065 | 0.83 | SPPL2A (0.55) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL2575749 | 0.82 | CYP3A4 (0.54) | SPPL2ARENCTSDMLNRABCB11 | |
| SCHEMBL13840781 | 0.82 | CYP3A4 (0.54) | SPPL2ARENCTSDMLNRABCB11 | |
| SCHEMBL12173888 | 0.82 | SPPL2A (0.54) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL11988963 | 0.81 | SPPL2A (0.63) | SPPL2ACTSDMLNRABCB11LMNA | |
| SCHEMBL9123183 | 0.81 | SPPL2A (0.49) | SPPL2ACTSDMLNRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | claimed |
| JP-3657002-B2 | — | — | 2005-06-08 | — | — | JP | claimed |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2004-11-18 | — | — | US | claimed |
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-10-09 | — | — | US | claimed |
| US-6455581-B1 | INHIBITORS OF HIV PROTEASE. | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | claimed |
| EP-0715618-B1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-12-16 | — | — | EP | claimed |
| EP-0656887-B1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-10-28 | — | — | EP | claimed |
| WO-1995006030-A1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | claimed |
| WO-1994004492-A1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | claimed |
| EP-0715618-B1 | HYDROXYETHYLAMINO SULPHONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0656887-B1 | HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1998-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191319-A1 | Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | SPPL2A 180/4885PSMB1 116/4885ADORA3 3544/4885 |
| US-20040229922-A1 | Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | DNPEP, ASPH, PREP | SPPL2A 180/4885PSMB1 116/4885ADORA3 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.